Compositions containing inclusion complexes

Details Compositions containing inclusion complexes Compositions containing inclusion complexes

2006-03-28

2006-03-28

Richter, Johann (Department: 1621)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an inorganic compound

C424S001690

Reexamination Certificate

active

07018609

ABSTRACT:
The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:

REFERENCES:
patent: 4887778 (1989-12-01), Soth et al.
patent: 5276088 (1994-01-01), Yoshinaga
patent: 5608015 (1997-03-01), Yoshinaga
patent: 5691316 (1997-11-01), Agrawal et al.
patent: 5698535 (1997-12-01), Geczy et al.
patent: 5855900 (1999-01-01), Nobuhiko
patent: 5880154 (1999-03-01), Boukrinskaia et al.
patent: 6048736 (2000-04-01), Kosak
patent: 6060597 (2000-05-01), Tobe et al.
patent: 6132734 (2000-10-01), Thomas et al.
patent: 6667293 (2003-12-01), Zhao et al.
patent: 2001/0034333 (2001-10-01), Kosak
patent: 2001/0044412 (2001-11-01), Wolf et al.
patent: 1 390 479 (1975-04-01), None
patent: WO 96/09073 (1996-03-01), None
patent: 99/47172 (1999-09-01), None
patent: WO 00/01734 (2000-01-01), None
patent: WO 00/33885 (2000-06-01), None
patent: WO 00/40692 (2000-07-01), None
patent: WO 00/75162 (2000-12-01), None
patent: WO 00/75164 (2000-12-01), None
patent: WO 01/37665 (2001-05-01), None
Husain, et al., “Complexation of Doxorubicin with β- and γ-Cyclodextrins,”Applied Spectroscopy, vol. 46, No. 4, pp. 652-658, (1992).
Hwang, et al., “Effects of Structure of γ-Cyclodextrin-Containing Polymers on Gene Delivery,”Bioconjugate Chem., vol. 12, No. 2, pp. 280-290 (2001).
Ooya, et al., “Synthesis and Characterization of an Oligopeptide-terminated Polyrotaxane as a Drug Carrier,”Polym. Adv. Technol., vol. 11, pp. 642-651 (2000).
Pun, et al., “Development of a Nonviral Gene Delivery Vehicle for Systemic Application,”Bioconjugate Chem., vol. 13, pp. 630-639, (2002).
Sandier, “Interaction between an Adamantane End-Capped Poly(ethylene oxide) and a γ-Cyclodextrin Polymer,”Langmuir, vol. 16, No. 4, pp. 1634-1642 (2000).
Tabushi et al., “Artificial Receptor Recognizing Hydrophobic Carbonyl Compounds,”Journal of Organic Chemistry, 51 (10), pp. 1918-1921 (1986).
Tojima, et al., “Preparation of an α-Cyclodextrin-Linked Chitosan Derivative via Reductive Amination Strategy,”J. Polym. Sci, Part A: Polym. Chem., vol. 36, pp. 1965-1968 (1998).
Torchilin, et al., “TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors,”PNAS, vol. 98, No. 15, pp. 8786-8791 (2001).
Uekama, et al., “Cyclodextrin Drug Carrier Systems,”Chem. Rev., 98, pp. 2045-2076 (1998).
Zanta, et al., “In Vitro Gene Delivery to Hepatocytes with Galactosylated Polyethylenimine,”Bioconjugate Chem., vol. 8, pp. 839-844 (1997).
Zhang, et al., “Enthalpic Domination of the Chelate Effect in Cyclodextrin Dimers,”J. Am. Chem. Soc., vol. 115, pp. 9353-9354 (1993).
Amiel, et al., “Associations Between Hydrophibically End-Capped Polyethylene Oxide and Water Soluble β Cyclodextrin Polymers,”Int. J. Polymer Analysis&Characterization, vol. 1, pp. 289-300 (1995).
Amiel, et al., “New Associating Polymer Systems Involving Water Soluble β-Cyclodextrin Polymers,”Journal of Inclusion Phenomena and Molecular Recognition in Chemistry, vol. 25, pp. 61-67(1996).
Amiel, et al., “Association between amphiphilic poly(ethylene oxide) and β-cyclodextrin polymers: aggregation and phase separation,”Advances in Colloid and Interface Science, 79, pp. 105-122 (1999).
Boussif, et al., “A versatile vector for gene and oligonocleotide transfer into cells in culture and in vivo: Polyethyleninmine,”Proceedings of the National Academy of Sciences, vol. 92, No. 16, pp. 7297-7301 (1995).
Breslow, et al., “Cholesterol Recognition and Binding by Cyclodextrin Dimers,”J. Am. Chem. Soc., vol. 118, pp. 8495-8496 (1996).
Cserháti, “Charge-Transfer Chromatographic Study of the Complex Formation of Some Anticancer Drugs with γ-Cyclodextrin,”Analytical Biochemistry, 225, pp. 328-332 (1995).
Finsinger, et al., “Protective copolymers for nonviral gene vectors: synthesis, vector characterization and application in gene delivery,”Gene Therapy, vol. 7, pp. 1183-1192 (2000).
Fisher, “A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression,”Gene Therapy, vol. 7, pp. 1337-1343 (2000).
Gonzalez, et al., “New Class of Polymers for the Delivery of Macromolecular Therapeutics,”Bioconjugate Chem., vol. 10, No. 6, pp. 1068-1074 (1999).
“Amantadine,” in The Merck Index, 11th ed., Merck Research Laboratories, p. 60:No. 380 (1989).
“Adamantane,” in The Merck Index, 11th ed., Merck Research Laboratories, p. 24: No. 140 (1989).

Affiliated with

Also associated with

Rating

Compositions containing inclusion complexes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions containing inclusion complexes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions containing inclusion complexes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3608481